Skip to main content

Updates & announcements

Discover the latest news on partnerships, events, projects of the Ulisse Biomed Group.

Ulisse Biomed supports the fight against malaria

Recently, Bill Gates shared his plan to donate most of his wealth over the next 20 years to the Gates Foundation, with a significant focus on solving global health problems.

The innovative soul of Ulysses Biomed: the research and development that drives our future

Hyris expands testing rapid technology aimed at supporting the fight against malaria

29 January 2025

New partnership agreement with Capebio

20 January 2025

NEW DISTRIBUTION AGREEMENT WITH MONTEBELLO DIAGNOSTICS

18 December 2024

A new brand identity for the Group

09 December 2024

Microbiota: a market with high potential

18 October 2024

Ulisse Biomed's HPV solutions confirmed among global best practices

10 September 2024

SMART GENE DESIGN - ERDF PR 2021-27 Line of action a1.2.1. Incentives to enterprises for process and organisational innovation activities - ULISSE BIOMED S.P.A.

The importance of genotyping in HPV screening

ULISSE BIOMED AND IKONISYS ANNOUNCE STRATEGIC PARTNERSHIP TO SUPPORT INNOVATION IN CANCER DIAGNOSTICS

New distribution agreement with GrowBIGOgh

Hyris signs a distribution agreement with GrowBIGogh

20 February 2024

Hyris technology supports the fight against one of the world’s deadliest diseases, malaria.

15 January 2024

Hyris fulfils its integration into Ulisse Biomed to give birth to a new international group ready to make its mark in the global biotech market.

10 January 2024

Distribution agreement renewal with Biomol Laboratories, fostering the partnership in the field of personalised medicine

28 December 2023

NEW AGREEMENT BETWEEN HYRIS AND CREA FOR THE DEVELOPMENT OF AGRICULTURAL TESTING

13 December 2023

NEW CLINICAL STUDY ON HPV SELFY PUBLISHED

04 December 2023

Hyris' signed a binding agreement for a reverse take-over, leading to a new integrated entity with Ulisse Biomed

29 September 2023

Hyris' new onboarding programs support researchers and developers to launch testing kits.

Hyris Founder&CEO Stefano Lo Priore interviewed by Carter&Benson

18 November 2022

Hyris and Singlabs signed a distributorship agreement for Singapore

02 November 2022

Hyris and P.Intertrade Equipments signed a distributorship agreement for Thai market.

27 September 2022

Hyris to participate to SIBioC 2022 in Genova, presenting Hyris marketplace approach for laboratory medicine

20 September 2022

Hyris to participate in SEI 2022 in Leon, hosted by the Sociedad Española de Immunologia

Hyris' new T-cell Test is finally available to EU Countries to easily map patients' cellular immunity to SARS-CoV-2

Hyris presented Hyris System, its distruptive signature technology, at Analytica 2022 in Munich

HPV SELFY INSERITO NEL RAPPORTO DEL GISCi SUI TEST HPV VALIDATI PER LO SCREENING DEL CARCINOMA DELLA CERVICE UTERINA

A new T-cell activation assay based on Hyris technology marks a disruptive approach for the detection of SARS-CoV-2 specific cellular immunity.

COVID-19: IL VALORE PROGNOSTICO DEI LIVELLI DI ALBUMINA E LE SUE IMPLICAZIONI

ULISSE BIOMED PARTECIPA AL CONVEGNO "ADENOCARCINOMA: SCREENING O UNA DIAGNOSI PRECOCE? UNA NUOVA SFIDA DOPO UN DECENNIO DI TEST HPV"

HPV SELFY: PRIMO HPV TEST DI GENOTIPIZZAZIONE COMPLETA VALIDATO PER LO SCREENING DEL CARCINOMA DEL COLLO DELL’UTERO SU CAMPIONI AUTO-PRELEVATI

COVID TEST SMART PRODUCTION POR FESR 1.2.a.1. BANDO 2020 - ULISSE BIOMED S.P.A.

NUOVA PUBBLICAZIONE A SUPPORTO DI UNA TECNOLOGIA BREVETTATA DA ULISSE BIOMED

ULISSE BIOMED PARTECIPA A EUROGIN 2022

PROGETTO NANOHYBRID - ANTICIPAZIONE PR FESR 2021–2027 - ULISSE BIOMED S.P.A.

Hyris and its network want to make pragmatic impact Helping Ukrainian Families

08 February 2022

POR FESR 2.3.b.1.bis

08 February 2022

POR FESR 2.3.b.1.bis (2)

21 December 2021

Hyris presented its new, disruptive T-Cell test at the international conference "A-Wish", fully embracing the Immunology sector to better fight COVID-19 and beyond.

02 December 2021

Hyris releases its new Demo to better support all prospect users of its portable and reliable molecular test for diagnosing SARS-CoV-2 into human subjects.

14 October 2021

Hyris new Test can quickly detect the body's T Cell immune response to SARS-CoV-2.

15 September 2021

Hyris presents its new Brand, supporting its fast growth worldwide.

The Hyris System™ can detect SARS-CoV-2 despite all the novel variants - Update

The Canadian Olympic Committee and Canadian Paralympic Committee chose the HYRIS SYSTEM™ to effectively test Canadian National Sport Teams against Covid-19.

22 February 2021

The Hyris System™ can detect SARS-CoV-2 despite all the novel variants

11 February 2021

Lallemand Health Solutions choose the Hyris System™ for their internal certification protocol

31 December 2020

Evaluation of the diagnostic accuracy of a new point-of-care rapid test for SARS-CoV-2 virus detection

30 October 2020

COMMUNICATION OF CONCESSION POR FESR 2014-2020

20 October 2020

Industry Leaders Embrace Hyris' "Virus Finder System" to Keep Operations Running and Employees Safe

30 September 2020

PFS Partner Hyris Secures UK Triumph with Canadian Government 90-Minute COVID-19 Testing Megadeal

Hyris Ltd first ranking for COVID-19 research fund program by Regione Lombardia

Hyris Ltd on Immunological Reviews - Application of a portable instrument for rapid and reliable detection of SARS-CoV-2 infection in any environment

Hyris COVID-19 Environmental Testing - Press Release

17 February 2020

Generon - Hyris

17 December 2018

POR FESR 2.3.b.1.bis

10 December 2018

CONCESSION OF POR FESR 1.3.B (2017)